Propanc Biopharma (Nasdaq: PPCB) has requested a foreign filing license from Spain for two provisional patents covering methods to treat resistant cancer and fibrosis. The provisional patents will be filed with IP Australia under Propanc Pty Ltd and are expected to be pursued in key global jurisdictions.The fibrosis provisional is described as a world-first expansion of PRP proenzyme therapy beyond cancer. Propanc says its planned Phase 1b First‑In‑Human study in 2026 will define PRP dosing ahead of Phase 2 proof‑of‑concept studies.

Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported financial results

In a first-of-its-kind initiative in the country, the Punjab Pollution Control Board (PPCB) has summoned 14 leading national and multinational brands,

CryptoMarket and Blockchain News

CryptoMarket and Blockchain News

Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent

Propanc Biopharma (NASDAQ: PPCB) announced a strategic initiative on Nov 4, 2025 to pursue acquisitions of Digital Asset Treasury (DAT) companies trading below Market Cap to Net Asset Value (MNAV). Management said acquiring undervalued DATs could strengthen Propanc's balance sheet, diversify assets, and create long-term shareholder value while the company continues its oncology development work.The release cites public data showing Bitcoin treasury companies hold approximately $76.9 billion and Ethereum-based DATs hold about $17.6 billion in digital assets. Propanc's board is evaluating targets and building due diligence frameworks and will update shareholders as qualified targets are identified.

Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing

Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing treatments for recurring and metastatic cancer, announced its fiscal year-end update following the filing of its annual

Nasdaq-listed biotech Propanc Biopharma announces plans to purchase $100M in Ethereum over 12 months. Strategy aims to diversify assets while funding cancer drug development and IP acquisitions.

Biotech firm Propanc raises $4M in Nasdaq IPO to advance PRP cancer treatment into Phase 1B trials. Drug targets $18.1B market for pancreatic/ovarian cancers. First human trials set for 2026.

The National Green Tribunal (NGT) has issued a notice to the state government and ordered a stay on the utilisation of the funds of Punjab Pollution Control Board (PPCB) and Forest and Wildlife Conservation Department till September 3, claimed the civil society group Public Action Committee (PAC). The directions came after The Tribune, on August 8, highlighted how the state government had directed various departments to deposit a total of Rs 1,441.49 crore, including Rs 250 crore from the PPCB and Rs 84 crore from the Forest Department. Taking cognisance of the news report, PAC, comprising environmentalists, approached the tribunal seeking a freeze on fund transfers.